Cargando…

Quantifying and predicting the effect of anti-TNF therapy on axSpA-related fatigue: results from the BSRBR-AS registry and meta-analysis

OBJECTIVES: Effective management of axial spondyloarthritis (axSpA)-related fatigue is a major unmet clinical need. Anti-TNF therapy may reduce fatigue levels, although any effect has yet to be definitively quantified and predictors of any such improvements are unknown. METHODS: The British Society...

Descripción completa

Detalles Bibliográficos
Autores principales: Shim, Joanna, Dean, Linda E, Karabayas, Maira, Jones, Gareth T, Macfarlane, Gary J, Basu, Neil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590410/
https://www.ncbi.nlm.nih.gov/pubmed/32337555
http://dx.doi.org/10.1093/rheumatology/keaa132
_version_ 1783600796216066048
author Shim, Joanna
Dean, Linda E
Karabayas, Maira
Jones, Gareth T
Macfarlane, Gary J
Basu, Neil
author_facet Shim, Joanna
Dean, Linda E
Karabayas, Maira
Jones, Gareth T
Macfarlane, Gary J
Basu, Neil
author_sort Shim, Joanna
collection PubMed
description OBJECTIVES: Effective management of axial spondyloarthritis (axSpA)-related fatigue is a major unmet clinical need. Anti-TNF therapy may reduce fatigue levels, although any effect has yet to be definitively quantified and predictors of any such improvements are unknown. METHODS: The British Society of Rheumatology Register in Axial Spondyloarthritis (BSRBR-AS) prospectively recruited axSpA patients across the UK. Changes in fatigue levels (measured using the Chalder Fatigue Scale) >1 year were compared between those starting anti-TNF therapy at the time of recruitment and those not. Differences between treatment groups were adjusted using propensity score matching. Results were meta-analysed with the extant literature to calculate pooled estimates. Then, among those BSRBR-AS anti-TNF commencers with clinically relevant fatigue, baseline predictors of response were investigated. RESULTS: Of the 998 BSRBR-AS recruits with complete fatigue data, 310 were anti-TNF commencers. At 1-year follow-up, the former group reported a mean fatigue change of −2.6 (95% CI −4.1, −1.9) points while the latter reported a mean worsening of fatigue by 0.2 points. Following propensity score adjustment, those commencing anti-TNF therapy reduced fatigue by 3.0 points compared with those not. Of those with significant fatigue and commencing anti-TNF, poor sleep quality at baseline predicted fatigue improvement. In the meta-analysis, including 1109 subjects, treatment with anti-TNF therapy resulted in a significant improvement in fatigue [Standardized mean difference (SMD) = 0.36, 95% CI 0.15, 1.56]. CONCLUSION: Anti-TNF therapy results in a significant but modest reduction in fatigue amongst axSpA patients, with those reporting poor sleep quality most likely to report improvement. Effective management will likely require additional approaches.
format Online
Article
Text
id pubmed-7590410
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-75904102020-10-30 Quantifying and predicting the effect of anti-TNF therapy on axSpA-related fatigue: results from the BSRBR-AS registry and meta-analysis Shim, Joanna Dean, Linda E Karabayas, Maira Jones, Gareth T Macfarlane, Gary J Basu, Neil Rheumatology (Oxford) Clinical Science OBJECTIVES: Effective management of axial spondyloarthritis (axSpA)-related fatigue is a major unmet clinical need. Anti-TNF therapy may reduce fatigue levels, although any effect has yet to be definitively quantified and predictors of any such improvements are unknown. METHODS: The British Society of Rheumatology Register in Axial Spondyloarthritis (BSRBR-AS) prospectively recruited axSpA patients across the UK. Changes in fatigue levels (measured using the Chalder Fatigue Scale) >1 year were compared between those starting anti-TNF therapy at the time of recruitment and those not. Differences between treatment groups were adjusted using propensity score matching. Results were meta-analysed with the extant literature to calculate pooled estimates. Then, among those BSRBR-AS anti-TNF commencers with clinically relevant fatigue, baseline predictors of response were investigated. RESULTS: Of the 998 BSRBR-AS recruits with complete fatigue data, 310 were anti-TNF commencers. At 1-year follow-up, the former group reported a mean fatigue change of −2.6 (95% CI −4.1, −1.9) points while the latter reported a mean worsening of fatigue by 0.2 points. Following propensity score adjustment, those commencing anti-TNF therapy reduced fatigue by 3.0 points compared with those not. Of those with significant fatigue and commencing anti-TNF, poor sleep quality at baseline predicted fatigue improvement. In the meta-analysis, including 1109 subjects, treatment with anti-TNF therapy resulted in a significant improvement in fatigue [Standardized mean difference (SMD) = 0.36, 95% CI 0.15, 1.56]. CONCLUSION: Anti-TNF therapy results in a significant but modest reduction in fatigue amongst axSpA patients, with those reporting poor sleep quality most likely to report improvement. Effective management will likely require additional approaches. Oxford University Press 2020-04-26 /pmc/articles/PMC7590410/ /pubmed/32337555 http://dx.doi.org/10.1093/rheumatology/keaa132 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Clinical Science
Shim, Joanna
Dean, Linda E
Karabayas, Maira
Jones, Gareth T
Macfarlane, Gary J
Basu, Neil
Quantifying and predicting the effect of anti-TNF therapy on axSpA-related fatigue: results from the BSRBR-AS registry and meta-analysis
title Quantifying and predicting the effect of anti-TNF therapy on axSpA-related fatigue: results from the BSRBR-AS registry and meta-analysis
title_full Quantifying and predicting the effect of anti-TNF therapy on axSpA-related fatigue: results from the BSRBR-AS registry and meta-analysis
title_fullStr Quantifying and predicting the effect of anti-TNF therapy on axSpA-related fatigue: results from the BSRBR-AS registry and meta-analysis
title_full_unstemmed Quantifying and predicting the effect of anti-TNF therapy on axSpA-related fatigue: results from the BSRBR-AS registry and meta-analysis
title_short Quantifying and predicting the effect of anti-TNF therapy on axSpA-related fatigue: results from the BSRBR-AS registry and meta-analysis
title_sort quantifying and predicting the effect of anti-tnf therapy on axspa-related fatigue: results from the bsrbr-as registry and meta-analysis
topic Clinical Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590410/
https://www.ncbi.nlm.nih.gov/pubmed/32337555
http://dx.doi.org/10.1093/rheumatology/keaa132
work_keys_str_mv AT shimjoanna quantifyingandpredictingtheeffectofantitnftherapyonaxsparelatedfatigueresultsfromthebsrbrasregistryandmetaanalysis
AT deanlindae quantifyingandpredictingtheeffectofantitnftherapyonaxsparelatedfatigueresultsfromthebsrbrasregistryandmetaanalysis
AT karabayasmaira quantifyingandpredictingtheeffectofantitnftherapyonaxsparelatedfatigueresultsfromthebsrbrasregistryandmetaanalysis
AT jonesgaretht quantifyingandpredictingtheeffectofantitnftherapyonaxsparelatedfatigueresultsfromthebsrbrasregistryandmetaanalysis
AT macfarlanegaryj quantifyingandpredictingtheeffectofantitnftherapyonaxsparelatedfatigueresultsfromthebsrbrasregistryandmetaanalysis
AT basuneil quantifyingandpredictingtheeffectofantitnftherapyonaxsparelatedfatigueresultsfromthebsrbrasregistryandmetaanalysis